Celon Pharma

Celon Pharma Current Assets

The Current Assets of Celon Pharma (CLN.WA) as of Oct 24, 2026 is 50.09 M PLN. In the previous year, Current Assets was 168.40 M PLN — a change of -70.25% (lower).

Current Assets

50.09 MPLN

YoY

-70.25%

Last updated:

Current Assets of Celon Pharma is 2025 50.09 M PLN. Current Assets of Celon Pharma was 2024 168.40 M PLN. It decreases by -70.25% lower compared to the previous year.

The Celon Pharma Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
253.88 M PLN
Jan 1, 2019
148.29 M PLN
Jan 1, 2020
123.26 M PLN
Jan 1, 2021
278.70 M PLN
Jan 1, 2022
237.58 M PLN
Jan 1, 2023
189.75 M PLN
Jan 1, 2024
168.40 M PLN
Jan 1, 2025
50.09 M PLN
The Celon Pharma Current Assets history
YEARCurrent AssetsYoY
50.09 MPLN-70.25%
168.40 MPLN-11.25%
189.75 MPLN-20.13%
237.58 MPLN-14.75%
278.70 MPLN+126.12%
123.26 MPLN-16.88%
148.29 MPLN-41.59%
253.88 MPLN+0.51%
252.59 MPLN-7.05%
271.75 MPLN+516.59%
44.07 MPLN+325.68%
10.35 MPLN-37.81%
16.65 MPLN+62.01%
10.28 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celon Pharma Stock analysis

What does Celon Pharma do? Celon Pharma SA develops and manufactures generic drugs for cancer, neurological diseases, diabetes, and metabolic disorders. Its product portfolio includes pills like Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder Salmex. The company operates through its research center focused on oncology, neurology, and inflammatory and metabolic diseases. As a subsidiary of Glatton sp z o o, Celon Pharma SA serves healthcare providers and patients seeking affordable treatment options for chronic conditions. Celon Pharma SA's revenue comes from selling its generic drug portfolio to pharmacies, hospitals, and healthcare institutions. The firm's products target patients with conditions such as cancer, neurological disorders, and diabetes, where cost-effective alternatives are in demand. Glatton sp z o o, the parent company, likely oversees strategic direction and resource allocation for Celon Pharma SA's operations. The company's focus on generic drugs positions it within the pharmaceutical market segment for affordable treatments. Its research center develops new formulations within therapeutic areas like oncology and neurology, supporting ongoing product innovation. Celon Pharma SA's product lineup, including inhalation powder Salmex and pill-based treatments, caters to specific medical needs across multiple disease categories. Celon Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celon Pharma stock

Current Assets of Celon Pharma is 50.09 M PLN in 2025.

Current Assets of Celon Pharma changed from 168.40 M PLN to 50.09 M PLN, representing a -70.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Celon Pharma since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Celon Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celon Pharma

All Key Metrics — Celon Pharma